Research Studies

Molnupiravir & Nirmatrelvir/Ritonavir in the Treatment of Systemic Autoimmune Rheumatic Diseases

Molnupiravir (MP) and Nirmatrelvir/ritonavir (NM/R) were the first two orally administered antiviral drugs authorized to treat COVID-19. However, the last two phases of clinical trials testing MP and NM/R in COVID-19 were conducted in unvaccinated individuals and before the emergence of the Omicron variant. Additionally, clinical trials didn’t include people suffering from systemic autoimmune rheumatic diseases (SARDs).

Read More »

Caring for Autoimmunity & Long COVID with a Personalized Approach

The company Mymee recently published a study on their personalized digital care program for patients living with autoimmune diseases as well as long Covid. Researchers found that over 85% of patients with moderate to severe symptoms saw improvements with their anxiety, depression, fatigue, pain interference, sleep disturbance, and pain intensity while increasing cognitive and physical function.

Read More »

COVID-19 Does Not Increase Risk of Celiac Disease

Researchers in Sweden used 1.4 million health records to examine the rate of new Celiac disease diagnoses in those who had experienced a COVID-19 infection versus those who had not. Findings suggested that respiratory diseases do not increase the risk of developing Celiac disease the way gastrointestinal infections do.

Read More »

T-cell Responses in Long Covid Patients

In a research letter on long Covid and pulmonary sequelae of COVID-19, authors shared findings around the possibility of viral reservoirs causing prolonged T-cell response in COVID-19 affected patients. The main finding indicated that prolonged infection led to T-cell exhaustion, especially in patients with abnormal lung function and/or structure following a COVID-19 infection.

Read More »